1-9 of 9
Frank L.J. Visseren
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907

Helena Bleken Østergaard, Joep van der Leeuw, Frank L.J. Visseren, Jan Westerink
Journal: Diabetes Care
Diabetes Care 2021;44(6):e139
https://doi.org/10.2337/dc21-0364
Published: 18 June 2021
View article titled, Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907
Open the PDF for Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907 in another window
Journal Articles

Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial

Tamar I. de Vries, Jannick A.N. Dorresteijn, Yolanda van der Graaf, Frank L.J. Visseren, Jan Westerink
Journal: Diabetes Care
Diabetes Care 2019;42(10):1988–1994
https://doi.org/10.2337/dc19-0776
Published: 12 September 2019
View article titled, Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial
Open the PDF for Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial in another window
Includes: Supplementary data
Journal Articles

Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes

Nordin M.J. Hanssen, Jan Westerink, Jean L.J.M. Scheijen, Yolanda van der Graaf, Coen D.A. Stehouwer, Casper G. Schalkwijk, SMART Study Group, Ale Algra, Yolanda van der Graaf, Rick D.E. Grobbee, Guy E.H.M. Rutten, Frank L.J. Visseren, Gert Jan de Borst, Jaap L.J. Kappelle, Tim Leiner, Hendrik M. Nathoe
Journal: Diabetes Care
Diabetes Care 2018;41(8):1689–1695
https://doi.org/10.2337/dc18-0159
Published: 21 May 2018
View article titled, Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes
Open the PDF for Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes

Charlotte Koopal, Frank L.J. Visseren, Jan Westerink, Yolanda van der Graaf, Henry N. Ginsberg, Anthony C. Keech
Journal: Diabetes Care
Diabetes Care 2018;41(6):1244–1250
https://doi.org/10.2337/dc17-0968
Published: 22 February 2018
View article titled, Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes
Open the PDF for Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424–1430

Shahnam Sharif, Yolanda van der Graaf, Hendrik M. Nathoe, Harold W. de Valk, Frank L.J. Visseren, Jan Westerink, on behalf of the SMART Study Group
Journal: Diabetes Care
Diabetes Care 2016;39(10):e190–e191
https://doi.org/10.2337/dci16-0023
Published: 13 September 2016
View article titled, Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424–1430
Open the PDF for Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424–1430 in another window
Journal Articles

HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes

Shahnam Sharif, Yolanda van der Graaf, Hendrik M. Nathoe, Harold W. de Valk, Frank L.J. Visseren, Jan Westerink, on behalf of the SMART Study Group
Journal: Diabetes Care
Diabetes Care 2016;39(8):1424–1430
https://doi.org/10.2337/dc16-0155
Published: 23 May 2016
View article titled, HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes
Open the PDF for HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

The Relation Between HbA1c and Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease

Guido Kranenburg, Yolanda van der Graaf, Joep van der Leeuw, Hendrik M.W. Nathoe, Gert Jan de Borst, L. Jaap Kappelle, Frank L.J. Visseren, Jan Westerink
Journal: Diabetes Care
Diabetes Care 2015;38(10):1930–1936
https://doi.org/10.2337/dc15-0493
Published: 25 August 2015
View article titled, The Relation Between HbA<sub>1c</sub> and Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease
Open the PDF for The Relation Between HbA<sub>1c</sub> and Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease in another window
Includes: Supplementary data
Journal Articles

Body Weight, Metabolic Dysfunction, and Risk of Type 2 Diabetes in Patients at High Risk for Cardiovascular Events or With Manifest Cardiovascular Disease: A Cohort Study

Bas T. Franssens, Yolanda van der Graaf, L. Jaap Kappelle, Jan Westerink, Gert J. de Borst, Maarten J. Cramer, Frank L.J. Visseren, on behalf of the SMART Study Group
Journal: Diabetes Care
Diabetes Care 2015;38(10):1945–1951
https://doi.org/10.2337/dc15-0684
Published: 25 August 2015
View article titled, Body Weight, Metabolic Dysfunction, and Risk of Type 2 Diabetes in Patients at High Risk for Cardiovascular Events or With Manifest Cardiovascular Disease: A Cohort Study
Open the PDF for Body Weight, Metabolic Dysfunction, and Risk of Type 2 Diabetes in Patients at High Risk for Cardiovascular Events or With Manifest Cardiovascular Disease: A Cohort Study in another window
Includes: Supplementary data
Journal Articles

Presence of the Metabolic Syndrome Does Not Impair Coronary Collateral Vessel Formation in Patients With Documented Coronary Artery Disease

Jobien K. Olijhoek, MD, Jeroen Koerselman, MD, Peter P.Th. de Jaegere, MD, PHD, Marianne C. Verhaar, MD, PHD, Diederick E. Grobbee, MD, PHD, Yolanda van der Graaf, MD, PHD, Frank L.J. Visseren, MD, PHD, for the SMART Study Group
Journal: Diabetes Care
Diabetes Care 2005;28(3):683–689
https://doi.org/10.2337/diacare.28.3.683
Published: 01 March 2005
View article titled, Presence of the Metabolic Syndrome Does Not Impair Coronary Collateral Vessel Formation in Patients With Documented Coronary Artery Disease
Open the PDF for Presence of the Metabolic Syndrome Does Not Impair Coronary Collateral Vessel Formation in Patients With Documented Coronary Artery Disease in another window